INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.37
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.42

16 Apr
2024

0.050

OPEN

$2.41

2.11%

HIGH

$2.43

557,284

LOW

$2.35

TARGET
$2.325 -3.9% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 7.9 xxx
DPS (cps) xxx N/A 6.2 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 30.9 xxx
Dividend Yield xxx N/A 2.5% xxx
Div Pay Ratio(%) xxx N/A 77.5% xxx

Dividend yield today if purchased 3 years ago: 1.26%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.45

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx10.8
DPS All xxxxxxxxxxxxxxx6.0
Sales/Revenue xxxxxxxxxxxxxxx440.1 M
Book Value Per Share xxxxxxxxxxxxxxx160.1
Net Operating Cash Flow xxxxxxxxxxxxxxx71.4 M
Net Profit Margin xxxxxxxxxxxxxxx5.69 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx6.95 %
Return on Invested Capital xxxxxxxxxxxxxxx3.60 %
Return on Assets xxxxxxxxxxxxxxx3.09 %
Return on Equity xxxxxxxxxxxxxxx6.95 %
Return on Total Capital xxxxxxxxxxxxxxx5.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx17 M
Long Term Debt xxxxxxxxxxxxxxx348 M
Total Debt xxxxxxxxxxxxxxx365 M
Goodwill - Gross xxxxxxxxxxxxxxx444 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx34 M
Price To Book Value xxxxxxxxxxxxxxx2.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx44.0 M
Capex % of Sales xxxxxxxxxxxxxxx10.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx342 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx58 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

21/02/2024

5

Underweight

$1.85

-23.55%

First half revenue growth from Integral Diagnostics was below Morgan Stanley's estimates, while margin recovery appears to be slow despite Medicare indexation. This highlights the ongoing cost pressures. EBITDA was in line with estimates.

No FY24 numerical guidance was provided although the broker suspects leverage will trend down gradually. Morgan Stanley revises EPS estimates up by 7% for FY24 and 5% for FY25 as lower tax and interest offset lower EBITDA outcomes.

The broker retains an Underweight rating, believing the discount in the stock is warranted until a more positive margin outlook becomes  evident. Target is raised to $1.85 from $1.70. Industry view is In-Line.

FORECAST
Morgan Stanley forecasts a full year FY24 dividend of 6.10 cents and EPS of 7.65 cents.
Morgan Stanley forecasts a full year FY25 dividend of 7.80 cents and EPS of 9.86 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IDX STOCK CHART